# FAMEGLOW HOLDINGS LIMITED 亮晴控股有限公司

(Incorporated in the Cayman Islands with limited liability) Stock Code : 8603

# INTERIM REPORT 2022

FACE

### CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.

This report, for which the directors (the "Director(s)") of Fameglow Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "We") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange (the "GEM Listing Rules") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this report misleading.

## CONTENTS

	Page
Corporate Information	3
Financial Highlights	5
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	6
Condensed Consolidated Statement of Financial Position	7
Condensed Consolidated Statement of Changes in Equity	9
Condensed Consolidated Statement of Cash Flows	10
Notes to Condensed Consolidated Financial Statements	11
Management Discussion and Analysis	19
Corporate Governance and Other Information	27

## CORPORATE INFORMATION

### **BOARD OF DIRECTORS**

#### **Executive Directors**

Mr. Yip Chun Kwok Danny, MH (Chairman) Ms. Fu Chi Ching (Chief Executive Officer)

#### Independent Non-executive Directors

Mr. Kwok David Mr. Tan Pui Kwan Mr. Yu Chi Wing

#### **Audit Committee**

Mr. Yu Chi Wing *(Chairman)* Mr. Kwok David Mr. Tan Pui Kwan

#### **Remuneration Committee**

Mr. Kwok David *(Chairman)* Mr. Tan Pui Kwan Ms. Fu Chi Ching

#### **Nomination Committee**

Mr. Yip Chun Kwok Danny, MH *(Chairman)* Mr. Kwok David Mr. Yu Chi Wing

#### **AUTHORISED REPRESENTATIVES**

Mr. Yip Chun Kwok Danny, MH Ms. Fu Chi Ching

## COMPANY SECRETARY

Ms. Tam Tsz Yan

#### **COMPLIANCE OFFICER**

Ms. Fu Chi Ching

#### AUDITOR

McMillan Woods (Hong Kong) CPA Limited Certified Public Accountants 24/F, Siu On Centre 188 Lockhart Road Wan Chai Hong Kong

#### **REGISTERED OFFICE**

Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman, KY1-1111 Cayman Islands

#### HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Unit 304, Global Gateway Tower 63 Wing Hong Street Cheung Sha Wan Kowloon, Hong Kong

#### PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS

Conyers Trust Company (Cayman) Limited Cricket Square Hutchins Drive P.O. Box 2681 Grand Cayman KY1-1111 Cayman Islands

#### HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited Level 54, Hopewell Centre 183 Queen's Road East Hong Kong

#### **PRINCIPAL BANKER**

Bank of Communications Co., Ltd. Hong Kong Branch 20 Pedder Street Central, Hong Kong

#### **COMPANY'S WEBSITE**

www.fameglow.com

# STOCK CODE

8603

# **FINANCIAL HIGHLIGHTS**

Revenue of the Group for the six months ended 30 September 2022 amounted to approximately HK\$96.5 million (six months ended 30 September 2021: approximately HK\$111.2 million).

The Group generated net profit of approximately HK\$2.0 million for the six months ended 30 September 2022 (six months ended 30 September 2021: approximately HK\$9.8 million).

The board of directors (the "Board") did not recommend a payment of dividend for the six months ended 30 September 2022 (six months ended 30 September 2021: Nil).

The Board is pleased to report the unaudited condensed consolidated financial results of the Group for the six months ended 30 September 2022, together with the comparative unaudited figures for the corresponding period in 2021, as follows:

### CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

		Six months ended 30 September		
		2022	2021	
	NOTES	HK\$'000	HK\$'000	
		(Unaudited)	(Unaudited)	
Revenue	4	96,452	111,192	
Cost of inventories and consumables		(13,409)	(18,049)	
Other income	5	4,634	262	
Staff costs		(39,825)	(35,902)	
Rental and related expenses		(2,548)	(2,083)	
Depreciation of property,				
plant and equipment		(12,761)	(8,322)	
Depreciation of right-of-use assets		(9,395)	(11,860)	
Other expenses		(18,881)	(22,750)	
Finance costs	_	(2,112)	(2,532)	
Profit before taxation	6	2,155	9,956	
Taxation	7	(148)	(186)	
Profit and total comprehensive				
income for the period	1	2,007	9,770	
Earnings per chare				
Earnings per share	9	0.25	1.22	
– Basic (HK cents)	9	0.25	1.22	

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 30 SEPTEMBER 2022

	NOTES	As at 30 September 2022 HK\$'000 (Unaudited)	As at 31 March 2022 HK\$'000 (Audited)
Non-current assets			
Property, plant and equipment	10	100,227	95,806
Right-of-use assets	10	62,737	74,608
Deposits and prepayments		10,949	7,854
Deferred costs		-	881
		173,913	179,149
Current assets			
Inventories		9,244	12,001
Trade receivables	11	8,037	4,937
Deposits and prepayments		10,885	17,487
Contract costs		5,324	4,443
Bank balances and cash		19,291	1,642
		52,781	40,510

	NOTES	As at 30 September 2022 HK\$'000 (Unaudited)	As at 31 March 2022 HK\$'000 (Audited)
Current liabilities			
Trade payables	12	1,380	1,611
Other payables and accruals	12	16,094	8,755
Contract liabilities		115,590	107,049
Tax payables		883	1,080
Bank borrowings		15,462	14,285
Lease liabilities		23,885	23,807
		173,294	156,587
Net current liabilities		(120,513)	(116,077)
		(120,515)	(110,077)
Total assets less current liabilities		53,400	63,072
Non-current liabilities			
Lease liabilities		44,495	56,343
Provisions		2,594	2,573
Deferred tax liabilities		1,172	1,024
		1,172	1,024
		48,261	59,940
Net assets		5,139	3,132
Capital and reserves			
Share capital	13	8,000	8,000
Reserves	CI	(2,861)	(4,868)
		(2,001)	(4,000)
Total equity		5,139	3,132

### CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

	Share capital HK\$'000	Share premium HK\$'000	Other reserve HK\$'000	Accumulated losses HK\$'000	<b>Total</b> HK\$'000
As at 1 April 2022 (audited) Profit and total comprehensive income	8,000	64,107	(21,026)	(47,949)	3,132
for the period	-	-	-	2,007	2,007
As at 30 September 2022 (unaudited)	8,000	64,107	(21,026)	(45,942)	5,139
As at 1 April 2021 (audited) Loss and total	8,000	64,107	(21,026)	(39,171)	11,910
comprehensive expense for the period	_	_	_	9,770	9,770
As at 30 September 2021 (unaudited)	8,000	64,107	(21,026)	(29,401)	21,680

# CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

	Six months ended 30 September	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
NET CASH FROM OPERATING ACTIVITIES	23,339	14,679
NET CASH USED IN INVESTING ACTIVITIES	(6,867)	(10,248)
NET CASH FROM (USED IN) FINANCING ACTIVITIES	1,177	(13,881)
NET INCREASE/(DECREASE) IN CASH AND		
CASH EQUIVALENTS	17,649	(9,450)
CASH AND CASH EQUIVALENTS AS AT 1 APRIL	1,642	39,377
CASH AND CASH EQUIVALENTS AS AT 30 SEPTEMBER		
represented by bank balances and cash	19,291	29,927

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

#### 1. GENERAL INFORMATION

Fameglow Holdings Limited (the "Company") was incorporated in the Cayman Islands as an exempted company with limited liability on 2 March 2018 under the Companies Law Chapter 22 of the Cayman Islands. The shares of the Company were listed on GEM of The Stock Exchange on 15 October 2018 (the "Listing"). The immediate holding company of the Company is Equal Joy Holdings Limited ("Equal Joy"), which is incorporated in the British Virgin Islands ("BVI"), and is 50% and 50% owned by Ms. Fu Chi Ching ("Ms. Fu") and Mr. Yip Chun Kwok Danny ("Mr. Yip"), spouse of Ms. Fu (Mr. Yip together with Ms. Fu collectively known as the "Controlling Shareholders"). The addresses of the registered office and the principal place of business of the Company are disclosed in the section headed "Corporate Information" of this interim report.

The Company acts as an investment holding company and its subsidiaries are principally engaged in provision of treatment services and sale of skincare products in Hong Kong. The Company and its subsidiaries hereinafter referred to as the "Group". The condensed consolidated financial statements are presented in Hong Kong Dollar ("HK\$") which is also the functional currency of the Company and its principal subsidiaries.

#### 2. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard ("HKAS") 34 "Interim Financial Reporting" issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") as well as the applicable disclosure requirements of Chapter 18 of the Rules Governing the Listing of Securities on the GEM of the Stock Exchange.

As at 30 September 2022, the Group recorded net current liabilities of HK\$120,513,000. The net current liabilities arose mainly from the contract liabilities of HK\$115,590,000, which represented services to be performed and shall not result in any cash outflow of the Group eventually. The Group has been taking various cost control measures to tighten the costs of operations and implementing various strategies to enhance the Group's revenue, proactively negotiating with bankers to obtain credit facility to finance the Group's operation and the Controlling Shareholders agreed to provide financial support to finance the Group's working capital requirements.

Taking into account the above consideration, the directors of the Company are satisfied that the Group will have sufficient financial resources to meet its financial obligations as they fall due in the next twelve months from the end of the reporting period. Accordingly, the condensed consolidated financial statements have been prepared on a going concern basis.

#### 3. SIGNIFICANT ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Other than changes in accounting policies resulting from application of new and amendments to HKFRSs, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 September 2022 are the same as those followed in the preparation of the Group's annual financial statements for the year ended 31 March 2022, except for the adoption of the standards, amendments and interpretation issued by the HKICPA mandatory for the annual periods beginning on 1 April 2022. The effect of the adoption of these standards, amendments and interpretation is not material on these unaudited condensed consolidated financial statements.

#### 4. REVENUE AND SEGMENTAL INFORMATION

#### Revenue

Revenue represents the net amounts received and receivable arising from the provision of treatment services, sales of skincare products and the provision of training services in Hong Kong.

	Six months ended	
	30 September	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Revenue from the provision of treatment services	94,961	108,497
Sale of skincare products	384	565
Revenue from expiry of prepaid treatments	872	1,531
Revenue from the provision of training services	235	599
	96,452	111,192

#### Segment information

The financial information reported to the executive directors of the Company, being the chief operating decision maker ("CODM") for the purpose of resources allocation and performance assessment, the CODM reviews the overall results and financial position of the Group as a whole prepared based on same accounting policies. Accordingly, the Group has one single operating segment and no further discrete financial information nor analysis of this single segment is presented.

#### 5. OTHER INCOME

	Six months ended	
	30 September	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Government subsidies	4,272	_
Interest income from rental deposit	181	182
Others	181	80
	4,634	262

#### 6. PROFIT (LOSS) BEFORE TAXATION

Profit (loss) before taxation has been arrived at after charging:

	Six months ended 30 September	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Directors' remuneration	2,436	2,272
Other staff costs:		
Salaries, wages, commission, bonuses and allowances	36,249	32,672
Retirement benefit scheme contributions	1,140	958
Total staff costs	39,825	35,902
Consultancy fee for doctors (included in other expenses)	4,200	3,273
	-	
Depreciation of property, plant and equipment	12,761	8,322
Depreciation of right-of-use assets	9,395	11,860

	Six months ended	
	30 September	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Hong Kong:		
Current tax	-	-
Deferred tax	148	186
Income tax charge	148	186

On 21 March 2018, the Hong Kong Legislative Council passed The Inland Revenue (Amendment) (No. 7) Bill 2017 (the "Bill") which introduced the two-tiered profits tax rates regime. The Bill was signed into law on 28 March 2018 and was gazetted on the following day.

Under the two-tiered profits tax rates regime, the first HK\$2,000,000 of profits of qualifying group entity will be taxed at 8.25%, and profits above HK\$2,000,000 will be taxed at 16.5%. The profits of corporations not qualifying for the two-tiered profits tax rates regime will continue to be taxed at a flat rate of 16.5%.

For the six months ended 30 September 2022, Hong Kong Profits Tax is calculated at 8.25% on the first HK\$2,000,000 of the estimated assessable profits of one of the subsidiaries of the Company and at 16.5% on the estimated assessable profits above HK\$2,000,000 of that subsidiary. The profits of other group entities not qualified for the two-tier profits tax regime will continue to be taxed at a flat rate of 16.5%. (six months ended 30 September 2021: same).

#### 8. DIVIDEND

The Board did not recommend a payment of dividend for the six months ended 30 September 2022 (six months ended 30 September 2021: Nil).

#### 9. EARNINGS PER SHARE

The calculation of the basic earnings per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 September	
	2022	2021
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Profit for the period for the purposes of		
basic earnings per share	2,007	9,770
	Six month	
	30 Sept	
	2022 (Unaudited)	2021 (Unaudited)
Weighted average number of ordinary shares in issue for		
the purposes of basic earnings per share	800,000,000	800,000,000

No diluted earnings per share for both periods was presented as there were no potential ordinary shares in issue during both periods.

#### 10. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT AND RIGHT OF USE ASSETS

For the six months ended 30 September 2022, the Group acquired property, plant and equipment with aggregate cost of approximately HK\$17,182,000 (six months ended 30 September 2021: HK\$15,884,000).

For the six months ended 30 September 2022, the Group did not recognise the additions to rightof-use assets (six months ended 30 September 2021: Nil).

#### 11. TRADE RECEIVABLES

The customers usually settle the prepaid packages by credit cards and electronic payment system ("EPS"). For credit card payments, the banks will normally settle the amounts received, net of handling charges, within 90-180 days after trade date. Payment by EPS will normally be settled within one to two days. In addition, the trade receivables also include receivable from a department store for collecting customers' receipt of the sales counters on behalf of the Group where the credit period is 30 days.

An ageing analysis of the trade receivables, based on the invoice date, which approximate the revenue recognition date, is as follows:

	As at	As at
	30 September	31 March
	2022	2022
	HK\$'000	HK\$'000
	(Unaudited)	(Audited)
0–30 days	3,642	1
31–90 days	2,452	841
Over 90 days	1,943	4,095
	8,037	4,937

As at 30 September 2022 and 31 March 2022, included in the Group's trade receivables balance are debtors with aggregate carrying amount of HK\$248,000 and HK\$1,524,000 respectively which are past due as at the reporting date. The directors of the Company do not consider the amount as significant increase in credit risk with reference to the historical records, past experience and also available reasonable and supportive forward-looking information of these debtors, and the recurring overdue records of these debtors with satisfactory settlement history.

In order to minimise the credit risk, the directors of the Company have delegated a team responsible for monitoring procedures to ensure that follow-up action is taken to recover overdue debts. In addition, the Group measures lifetime ECL on trade receivables on individual basis at the end of the reporting period.

In view of the business nature, management of the Group considers that the credit risks of trade receivables are insignificant after considering the credit quality and financial ability of the relevant financial institutions and there is no history of default in settlement by them. In the opinion of the management of the Group, the risk of default by these counterparties is not significant and the Group assessed that the ECL on these balances are insignificant on 30 September 2022 and thus no impairment loss allowance was recognised for the six months ended 30 September 2022.

#### 12. TRADE PAYABLES

The credit period of trade payables is ranging from 0 to 30 days.

An ageing analysis of trade payables, based on invoice date, is as follows:

	As at	As at
	30 September	31 March
	2022	2022
	НК\$′000	HK\$'000
	(Unaudited)	(Audited)
0–30 days	1,377	1,611
31–90 days	43	-
	1,380	1,611

#### 13. SHARE CAPITAL

Details of the Company's shares are disclosed as follows:

Ordinary shares of HK\$0.01 each	Number of shares	<b>Amount</b> HK\$'000
Authorised: At 1 April 2021, 31 March 2022, 1 April 2022 and 30 September 2022	10,000,000,000	100,000
Issued and fully paid: At 1 April 2021, 31 March 2022, 1 April 2022 and 30 September 2022	800,000,000	8,000

The new shares issued rank pari passu in all aspects with existing shares.

#### 14. RELATED PARTY TRANSACTIONS

#### Compensation of key management personnel

The remuneration of key management personnel during the six months ended 30 September 2022 and 2021, respectively were as follows:

	Six months ended 30 September	
	2022	
	HK\$'000	HK\$'000
	(Unaudited)	(Unaudited)
Short-term benefits	2,418	3,045
Post-employment benefits	18	26
	2,436	3,071

#### 15. EVENT AFTER THE REPORTING PERIOD

There was no significant event which took place after 30 September 2022.

## MANAGEMENT DISCUSSION AND ANALYSIS

#### **BUSINESS REVIEW**

The Group is a medical aesthetic service provider in Hong Kong and operates medical aesthetic centres in prime locations of Causeway Bay, Tsim Sha Tsui, Mong Kok and Central providing non-surgical medical aesthetic services. We strive to provide holistic treatment solutions to our clients through our non-surgical medical aesthetic services, traditional beauty services and sale of skincare products to help our clients maintain and enhance their skin conditions and physical appearance.

The outlook of the medical aesthetic services industry remains optimistic with market demand growing fast in recent years, owed mainly to the increasing affordability and public acceptance of related services.

In order to seize the opportunity created by increasing customer demands, we expanded our operation scale by opening several new centres. In May 2021 and June 2022, we have launched a new flagship centre in Mong Kok and a prime new centre in Tsim Sha Tsui, to facilitate the continuous growth of our business. The Group believes that the expansion will enable us to deepen our market penetration in Hong Kong and improve our Group's profitability. The Group will also take advantage of its enlarging geographical presence to attract new and more diverse customers. Along with the strategic expansion of its medical aesthetic centre network, the Group will sharpen its competitive advantage by extending the spectrum of our treatment services offered.

However, for the six months ended 30 September 2022, the business environment in Hong Kong was adversely affected from Coronavirus Disease 2019 ("COVID-19") pandemic, the Group's revenue amounted to approximately HK\$96.5 million, representing a decrease of approximately HK\$14.7 million or 13.2% as compared with the corresponding period of 2021. Profit for the period amounted to approximately HK\$2.0 million, while profit for the corresponding period of approximately HK\$9.8 million. It was primarily attributable to the decrease in revenue as a result of the medical aesthetic centres of the Group were compulsory closed for certain period due to the outbreak of COVID-19 during the current period while there was no such impact during the corresponding period in 2021.

#### **PROSPECTS**

Despite the COVID-19 pandemic is still causing uncertainties to the business environment, the local economy has started on the path of recovery. As such, the outlook of medical aesthetic services remains positive and the Group will closely monitor the market conditions and will intensify its response and elaborate sustainable development strategies to capture opportunities under the current environment.

Nevertheless, the Group is confident of its capability to deliver quality service to our clients. Moving forward, the Group will apply its strengths, build on its solid customer base and established reputation to deliver stable business development and maximise the shareholders' value.

#### **FINANCIAL REVIEW**

#### Revenue

The revenue of the Group amounted to approximately HK\$96.5 million and approximately HK\$111.2 million for the six months ended 30 September 2022 and 2021 respectively which represented a decrease of approximately HK\$14.7 million or 13.2% as compared with the corresponding period of 2021. The decrease was primarily attributable to the medical aesthetic centres of the Group were compulsory closed for certain period due to the outbreak of COVID-19 during the current period while there was no such impact during the corresponding period in 2021.

#### **Cost of inventories and consumables**

Cost of inventories and consumables amounted to approximately HK\$13.4 million and HK\$18.0 million for the six months ended 30 September 2022 and 2021 respectively. The decrease was in line with the decline in revenue.

#### **Other income**

Other income amounted to approximately HK\$4.6 million and HK\$0.3 million for the six months ended 30 September 2022 and 2021 respectively. The increase in other income was mainly attributable to the Government subsidies granted under the antiepidemic fund during the current period.

#### **Staff costs**

Staff costs amounted to approximately HK\$39.8 million and HK\$35.9 million for the six months ended 30 September 2022 and 2021 respectively. The increase in staff costs was mainly due to the increased number of staff during the current period.

#### **Rental and related expenses**

Rental and related expenses amounted to approximately HK\$2.5 million and HK\$2.1 million for the six months ended 30 September 2022 and 2021 respectively, which comprised of management fees, rates and government rent and license fees for our medical aesthetic centres.

#### Depreciation of property, plant and equipment

Depreciation expenses amounted to approximately HK\$12.8 million and HK\$8.3 million for the six months ended 30 September 2022 and 2021 respectively. The increase was mainly due to the additions of the property, plant and equipment such as leasehold improvements and treatment devices.

#### **Depreciation of right-of-use assets**

The Group recorded depreciation of right-of-use assets of approximately HK\$9.4 million and HK\$11.9 million for the six months ended 30 September 2022 and 2021 respectively. The decrease was mainly due to the increased number of leases for new medical aesthetic centres during the corresponding period in 2021.

#### **Other expenses**

The breakdown of the other expenses is as follows:

	Six months ended 30 September	
	<b>2022</b> 202	
	HK\$'000	HK\$'000
Marketing and promotion expenses	8,711	11,310
Card commission	2,351	2,494
Consultancy fees to doctors	4,200	3,273
Professional fees	467	600
Repair and maintenance fees	1,127	1,394
Others	2,025	3,679
	18,881	22,750

Other expenses amounted to approximately HK\$18.9 million and HK\$22.8 million for the six months ended 30 September 2022 and 2021 respectively. The decrease was primarily due to the decrement in promotional campaigns such as outdoor advertising and advertising on various social media platforms.

#### Profit/(loss) for the period

The Group generated a net profit of approximately HK\$2.0 million for the six months ended 30 September 2022 (six months end 30 September 2021: approximately HK\$9.8 million). This was mainly due to the medical aesthetic centres of the Group were compulsory closed for certain period due to the outbreak of COVID-19 during the current period while there was no such impact during the corresponding period in 2021.

#### Capital structure, liquidity and financial resources

On 15 October 2018 (the "Listing Date"), the shares of the Company were listed on GEM by way of share offer. Please refer to the Company's prospectus dated 28 September 2018 (the "Prospectus") for more details of the share offer. The net proceeds from the share offer were approximately HK\$31.6 million, which was based on the share price of HK\$0.28 per share and the actual expenses related to the share offer. The Company believed that the funding from the share offer on the GEM would allow the Group to access the capital market for raising funds in the future. There has been no change on the capital structure of the Group since the Listing Date and up to the date of this report. The capital of the Company only comprises of ordinary shares.

The total equity of the Group as at 30 September 2022 was approximately HK\$5.1 million (31 March 2022: approximately HK\$3.1 million). The Group generally finances its operation with internally generated cash flows. The Group had bank balances and cash of approximately HK\$19.3 million as at 30 September 2022 (31 March 2022: approximately HK\$1.6 million). The Group had total outstanding debts of HK\$83.9 million as at 30 September 2022 (31 March 2022: approximately HK\$94.4 million), which comprised lease liabilities amounting to HK\$68.4 million (31 March 2022: approximately HK\$80.2 million) and bank borrowings amounting to approximately HK\$15.5 million (31 March 2022: approximately HK\$16.5 million).

As at 30 September 2022, bank borrowings of HK\$6.2 million and HK\$9.3 million (31 March 2022: HK\$5.7 million and HK\$8.6 million) will mature within one year and in the second year or above respectively. The interest rate of the bank borrowings is 2.75% (31 March 2022: 2.75%).

As at 30 September 2022, lease liabilities of HK\$23.9 million, HK\$20.8 million and HK\$23.7 million (31 March 2022: HK\$27.2 million, HK\$25.5 million and HK\$34.6 million) will mature within one year, in the second year and in the third year or above respectively. The weighted average effective interest rates of the lease liabilities range from 0.01% to 2.23% (31 March 2022: 0.01% to 2.23%).

#### **Capital expenditures**

The Group purchased property, plant and equipment amounting to approximately HK\$17.2 million for the six months ended 30 September 2022 which comprised acquisition of treatment devices, furniture and fixtures and leasehold improvements (six months ended 30 September 2021: HK\$15.9 million).

#### **Interim dividend**

The Board did not recommend a payment of dividend for the six months ended 30 September 2022 (six months ended 30 September 2021: Nil).

#### **Employees and remuneration policies**

As at 30 September 2022, the Company had a total of 206 employees (31 March 2022: 159). The Company's remuneration policies are in line with the prevailing market practice and are determined on the basis of performance, qualification and experience of individual employee. The Company recognises the importance of a good relationship with its employees. The remuneration payable to its employees includes basic salary, commission, discretionary bonus and retirement benefit scheme contributions.

#### **Principal risks and uncertainties**

The Group's financial condition, results of operations, and business prospects may be affected by a number of risks and uncertainties directly or indirectly pertaining to the Group's business. The following are the key risks and uncertainties identified by the Group.

#### Government policies risk

Following certain adverse incidents in relation to the beauty service industry in recent years, the Hong Kong Government has been reviewing the existing legal framework and considering tightening its supervision over the beauty service industry by promulgating certain laws and regulations to regulate, among other things, the types of medical aesthetic procedures that should be performed by registered medical practitioners.

There is no assurance that the Hong Kong Government will not impose more stringent laws, rules, regulations or industry standards in connection with the provision of medical aesthetic services. Any change in the regulatory framework may render it more restrictive for us to conduct our business. There is also no assurance that we will be able to adapt to such changes in a timely manner. In addition, compliance with such new laws, rules, regulations or industry standards may significantly increase our operating costs, which may in turn lower our profit margins. Any of the above-mentioned circumstances may materially and adversely affect our business, results of operations, financial condition and prospects.

#### Risk of adverse economic, social or political conditions

All of our business operations are based in and we derive all of our revenue from Hong Kong. Our business operations and the demand for our medical aesthetic services are therefore subject to the economic, social and political conditions in Hong Kong. Furthermore, any incidence of social unrest, strike, riot, civil disturbance or disobedience in Hong Kong may cause inconvenience to clients who wish to visit our medical aesthetic centres and weaken their desire or willingness to undergo medical treatments. Any of the above circumstances may have a material and adverse impact on our business, results of operations and financial condition.

#### Future plans for material investments and capital assets

As at 30 September 2022, the Group does not have any plans for material investments and capital assets.

# Significant investments, material acquisitions and disposal of subsidiaries and capital assets

The Group did not have any significant investments, material acquisitions and disposals of subsidiaries and capital assets during the period.

#### **Gearing ratio**

The gearing ratio, which is based on the total amounts of total bank borrowings and lease liabilities divided by total equity, was 1,631.5% as at 30 September 2022 (31 March 2022: 3,051.2%).

#### Foreign exchange exposure and treasury policies

The Group carries out its business in Hong Kong and most of its transactions are denominated in Hong Kong Dollar. The Group did not experience any material impact or difficulties in liquidity on its operations resulting from the fluctuation in exchange rate, and no hedging transaction or forward contract arrangement was made by the Group during the six months ended 30 September 2022 and 2021. Nevertheless, the management will continue to monitor the Group's foreign exchange exposure and will take prudent measures as and when appropriate.

#### **Contingent liabilities**

As at 30 September 2022, the Group had no significant contingent liabilities (31 March 2022: Nil).

#### Financial risk management

Risk management is carried out by the Group's finance department under policies approved by the Board. The finance department identifies, evaluates and hedges financial risks in close co-operation with the Group's operating units. The Board provides guidance for overall risk management and specific areas, such as market risk, interest rate risk, credit risk and liquidity risk.

#### **Bank borrowings**

As at 30 September 2022, the Group had unsecured and guaranteed bank borrowings of approximately HK\$15.5 million (31 March 2022: approximately HK\$14.3 million). As at 30 September 2022, the entire bank borrowings were guaranteed by personal guarantees from the Controlling Shareholders and HKMC Insurance Limited (31 March 2022: same).

#### **Pledge of assets**

As at 30 September 2022, the carrying amount of right-of-use assets included an amount of approximately HK\$1.6 million (31 March 2022: approximately HK\$2.0 million) representing treatment devices.

#### **Subsequent events**

There was no significant event which took place after 30 September 2022.

# CORPORATE GOVERNANCE AND OTHER INFORMATION

#### **CORPORATE GOVERNANCE PRACTICES**

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the shareholders of the Company (the "Shareholders") and to enhance corporate value and accountability. The Company has adopted the Corporate Governance Code (the "CG Code") as set out in Appendix 15 to the GEM Listing Rules as its own code of corporate governance. The Company has complied with all applicable code provisions of the CG Code during the six months ended 30 September 2022 and up to the date of this report. The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

#### COMPLIANCE WITH THE REQUIRED STANDARD OF DEALINGS IN SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the required standard of dealings set out in Rules 5.48 to 5.67 of the GEM Listing Rules as its own code of conduct regarding Directors' securities transactions. Having made specific enquiries of all the Directors, each of the Directors has confirmed that he has complied with the required standard of dealings for the six months ended 30 September 2022.

#### AUDIT COMMITTEE AND REVIEW OF INTERIM RESULTS

The Company has established an audit committee (the "Audit Committee") with written terms of reference in compliance with Rules 5.28 to 5.33 of the GEM Listing Rules and the CG Code. The Audit Committee comprises three members, namely Mr. Yu Chi Wing (chairman), Mr. Kwok David and Mr. Tan Pui Kwan, all of them are independent non-executive Directors. The Audit Committee has reviewed with the management the accounting policies and practices adopted by the Group and discussed with the management internal control and financial reporting matters of the Company, including the review of the unaudited condensed consolidated results of the Group for the six months ended 30 September 2022 and the interim report. The Audit Committee is of the opinion that the unaudited condensed consolidated results of the Group for the six months ended 30 September 2022 comply with the applicable accounting standards, the GEM Listing Rules and legal requirements and that adequate disclosure has been made.

# PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

During the six months ended 30 September 2022, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities.

#### DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 September 2022, the interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")) which were notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were recorded in the register required to be kept by the Company under Section 352 of the SFO, or which were, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules, notified to the Company and the Stock Exchange, were as follows:

#### Long position in the shares of the Company:

Name of director/ chief executive	Capacity/Nature of interest	Number of Shares held (Note i)	Percentage of shareholding
Mr. Yip	Interest in controlled corporation (Note ii)	562,000,000 (L)	70.25%
Ms. Fu	Interest in controlled corporation (Note ii)	562,000,000 (L)	70.25%

Notes:

(i) The letter "L" denotes the person's long position in the relevant Shares.

(ii) All the issued shares of Equal Joy are legally and beneficially owned as to 50% by each of Mr. Yip and Ms. Fu. Accordingly, they are deemed to be interested in the 562,000,000 Shares held by Equal Joy by virtue of the SFO. Mr. Yip, Ms. Fu and Equal Joy together are a group of Controlling Shareholders of the Company.

Save as disclosed above, as at 30 September 2022, none of the Directors or chief executive of the Company had any interest or short position in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO) which are required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or which are required to be recorded in the register required to be kept by the Company under Section 352 of the SFO, or which shall be, pursuant to Rules 5.46 to 5.67 of the GEM Listing Rules, notified to the Company and the Stock Exchange.

# SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 September 2022, to the knowledge of the Directors, the following persons/entities (other than the Directors or chief executive of the Company) who had or were deemed to have interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO were as follows:

Name of shareholder	Capacity/Nature of interest	Number of Shares held (Note i)	Percentage of shareholding
Equal Joy	Beneficial owner (Note ii)	562,000,000 (L)	70.25%

Notes:

(i) The letter "L" denotes the person's long position in the relevant Shares.

(ii) All the issued shares of Equal Joy are legally and beneficially owned as to 50% by each of Mr. Yip and Ms. Fu. Mr. Yip, Ms. Fu and Equal Joy together are a group of controlling shareholders of the Company. Save as disclosed above, as at 30 September 2022, the Directors were not aware of any other persons/entities (other than the Directors or chief executive of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

#### SHARE OPTION SCHEME

In order to incentivise and/or recognise and acknowledge the contributions that eligible persons have made or may make to the Group, the Company adopted the share option scheme pursuant to written resolutions of the Shareholders passed on 21 September 2018 (the "Share Option Scheme"). The Board may, at its discretion, offer to grant an option to any eligible persons.

Unless terminated by the Company by resolution in general meeting, the Share Option Scheme shall be valid and effective for a period of 10 years commencing from the date of adoption.

The purpose of the Share Option Scheme is to advance the interests of the Company and the Shareholders by enabling the Company to grant options to attract, retain and reward the eligible persons and to provide the eligible persons an incentive or reward for their contribution to the Group and by enabling such persons' contribution to further advance the interests of the Group. The terms of the Share Option Scheme are in accordance with provisions of Chapter 23 of GEM Listing Rules.

No option has been granted, exercised, cancelled or lapsed under the Share Option Scheme since its adoption. The Company did not have any outstanding share options, warrants, derivatives or securities which are convertible or exchangeable into Shares as at 30 September 2022 and up to the date of this report.

#### DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as otherwise disclosed in this interim report, at no time during the six months ended 30 September 2022 and up to the date of this report was the Company or any of its subsidiaries a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

# DIRECTORS' AND CONTROLLING SHAREHOLDERS' INTERESTS IN COMPETING BUSINESS

During the six months ended 30 September 2022, and up to the date of this report, none of the Directors or their respective associates had engaged in or had any interest in any business which competes or is likely to compete, either directly or indirectly, with the business of the Group and which requires disclosure pursuant to Rule 11.04 of GEM Listing Rules.

By Order of the Board Fameglow Holdings Limited Mr. Yip Chun Kwok Danny, MH Chairman and Executive Director

Hong Kong, 14 November 2022

As at the date of this report, the executive Directors are Mr. Yip Chun Kwok Danny, MH and Ms. Fu Chi Ching; and the independent non-executive Directors are Mr. Tan Pui Kwan, Mr. Kwok David and Mr. Yu Chi Wing.